Drug class

Beta-Blockers (Systemic)

Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body. Read more about Beta-Blockers (Systemic)

386 drugs in this class 143 manufacturers

Advertisement

Drugs in Beta-Blockers (Systemic)

Showing 370–378 of 386 drugs

CARVEDILOL

ALPHA-BETA BLOCKERS · HYPERTENSION ·+2
UNICHEM DBA SAW

NADOLOL

BETA-BLOCKERS (SYSTEMIC) · HYPERTENSION ·+1
UNICHEM DBA SAW

PINDOLOL

BETA-BLOCKERS (SYSTEMIC) · HYPERTENSION
UNICHEM DBA SAW

SOTALOL (sotalol HCl)

ANTIARRHYTHMIC - CLASS III · LIFE-THREATENING VENTRICULAR TACHYCARDIA ·+2
UNICHEM DBA SAW

LABETALOL HCL

ALPHA-BLOCKERS · HYPERTENSION
Avet Pharmaceuticals

NADOLOL

BETA-BLOCKERS (SYSTEMIC) · HYPERTENSION ·+1
A-S MEDICATION

ATENOLOL

BETA-BLOCKERS (SYSTEMIC) · HYPERTENSION ·+2
UNICHEM-IPCA

BETAPACE (sotalol HCl)

ANTIARRHYTHMIC - CLASS III · LIFE-THREATENING VENTRICULAR TACHYCARDIA ·+2
LEGACY PHARMA I
Filter & compare in the drug finder → Opens the drug finder with Beta-Blockers (Systemic) preselected. Add indication or manufacturer filters there.

About Beta-Blockers (Systemic).

Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body.

By blocking cardiac beta-1 and peripheral beta-2 receptors, these medications exert negative inotropic and chronotropic effects, slowing the heart rate, decreasing myocardial contractility, and lowering systemic arterial blood pressure.

They are primarily indicated across cardiovascular medicine for the management of hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, and chronic heart failure with reduced ejection fraction.

Additionally, systemic beta-blockers play key therapeutic roles in non-cardiovascular conditions, including migraine prophylaxis, essential tremor, and the symptomatic management of thyrotoxicosis.